Tonghua Dongbao Pharmaceuticals’ THDBH120 Receives NMPA Approval for Phase II Clinical Trial
Tonghua Dongbao Pharmaceuticals (SHA: 600867), based in China, has announced that the National Medical Products...
Company
DK Medical Technology Secures ‘Hundreds of Millions’ in Series E Financing for Expansion
DK Medical Technology Co. Ltd., a Suzhou-based developer of vascular intervention balloon products, has reportedly...
Shanghai Fudan-Zhangjiang and Hanhui Pharmaceutical End Marketing Deal for Libaoduo
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505), a Chinese biopharmaceutical company, has reached...
Luye Pharma’s Once-Weekly Parkinson’s Disease Treatment Receives NMPA Approval
Luye Pharma Group (HKG: 2186) has announced that it has received marketing approval from the...
Fudan-Zhangjiang Bio-Pharmaceutical Advances Aminolevulinic Acid Study for Glioma Visualization
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd (HKG: 1349; SHA: 688505) has announced that the first subject...
Novartis Moves Toward Full Ownership of MorphoSys with Shareholder Squeeze-Out
Novartis AG (NYSE: NVS), the Swiss pharmaceutical giant, is proceeding to fully acquire MorphoSys AG...
Dizal Pharmaceutical’s Golidocitinib Wins NMPA Approval for Relapsed/Refractory PTCL
Dizal Pharmaceutical Co., Ltd (SHA: 688192), a spin-off from AstraZeneca China established in 2017, has...
Shanghai Fosun Pharmaceutical Sells Stake in Gland Pharma for USD 211 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has announced the sale of...
Jiuzhou Pharmaceutical Shuts Down Two Subsidiaries to Streamline Operations
Zhejiang Jiuzhou Pharmaceutical Co., Ltd (SHA: 603456), a pharmaceutical company based in China, has announced...
Keymed Biosciences’ CM313 Shows Promise in Treating Immune Thrombocytopenia, NEJM Study Says
Keymed Biosciences Inc. (HKG: 2162), a biopharmaceutical company based in China, has published results from...
Xencor Reclaims Rights to Plamotamab After Janssen Halts Development
Xencor Inc. (NASDAQ: XNCR), a U.S.-based biotechnology company, has announced that Johnson & Johnson (J&J,...
AbbVie’s Skyrizi Secures FDA Approval for Ulcerative Colitis, Expands Treatment Portfolio
AbbVie (NYSE: ABBV) has announced that the U.S. Food and Drug Administration (FDA) has approved...
Genrix Biopharmaceutical and Chongqing Pharmaceutical Group Form Strategic Partnership to Boost Market Launch
Chongqing Genrix Biopharmaceutical Co., Ltd (SHA: 688443), a biopharmaceutical company based in China, has entered...
AstraZeneca’s Gracell Biotechnologies to Expand Cell Therapy Manufacturing in China
Gracell Biotechnologies, a China-based cell therapy specialist owned by AstraZeneca (AZ; NASDAQ: AZN), is reportedly...
NMPA Releases 81st Batch of Reference Drugs for Generic Quality Consistency Evaluation
The National Medical Products Administration (NMPA) has released the 81st batch of reference drugs for...
Grifols Completes Sale of 20% Stake in Shanghai RAAS to Haier Group for RMB 12.5 Billion
Grifols AS (NASDAQ: GRFS), a Spain-based global leader in the production of blood products, has...
3SBio Secures Long-Term Financing from IFC for Manufacturing and Global Expansion
3SBio Inc. (HKG: 1530), a biopharmaceutical company based in China, is slated to receive long-term...
Hybribio Ltd Secures NMPA Approval for α-Thalassemia Genotyping Detection Kit
Hybribio Ltd (SHE: 300639), a Guangdong-based provider of nucleic acid molecular diagnostic products, has announced...
Kanghong Pharmaceutical’s Lumitin Approved in Myanmar for Neovascular AMD Treatment
Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773), a Chinese pharmaceutical company, has announced that...
Suzhou Zelgen’s Recombinant Human Thyroid Stimulating Hormone Accepted for NMPA Review
Suzhou Zelgen Biopharmaceuticals Co., Ltd (SHA: 688266), a biopharmaceutical company based in China, has announced...